Suppr超能文献

微切口角膜基质透镜取出术(SMILE)治疗高度近视伴散光。

Small Incision Lenticule Extraction (SMILE) for the Correction of High Myopia With Astigmatism.

出版信息

J Refract Surg. 2022 May;38(5):262-271. doi: 10.3928/1081597X-20220314-01. Epub 2022 May 1.

Abstract

PURPOSE

To report the outcomes of small incision lenticule extraction (SMILE) for high myopia between -9.00 and -14.00 diopters (D).

METHODS

This was a prospective study of SMILE for high myopia using the VisuMax femtosecond laser (Carl Zeiss Meditec). Inclusion criteria were attempted spherical equivalent refraction (SEQ) between -9.00 and -14.00 D, cylinder up to 7.00 D, corrected distance visual acuity (CDVA) of 20/40 or better, age 21 years or older, and suitable for SMILE. The sub-lenticule thickness was 220 µm or greater, and the total uncut stromal thickness was 300 µm or greater. Patients were to be followed up for 1 year. Standard outcomes analysis was performed using 12-month data where available or 3-month data otherwise.

RESULTS

Of 187 eyes treated, data were available at 12 months for 181 eyes (96.8%) and 3 months for 4 eyes (2.1%), and 2 eyes (1.1%) were lost to follow-up. Mean attempted SEQ was -10.55 ± 1.00 D (range: -9.00 to -12.99 D). Mean cylinder was -1.19 ± 0.83 D (range: 0.00 to -4.00 D). Preoperative CDVA was 20/20 or better in 73% of eyes. Postoperative uncorrected distance visual acuity was 20/20 or better in 57% and 20/25 or better in 82% of eyes. Mean SEQ relative to target was -0.22 ± 0.48 D (range: -1.63 to +1.38 D), 66% ± 0.50 D and 93% ±1.00 D. Mean SEQ 12-month change was -0.08 ± 0.34 D (range: -1.75 to +0.88 D). There was loss of one line of CDVA in 4% of eyes, and no eyes lost two or more lines. Contrast sensitivity was unchanged. Patient satisfaction was 8 or more out of 10 in 94% and 6 or more in 99% of patients.

CONCLUSIONS

Outcomes of SMILE for myopia greater than -9.00 D at 3 to 12 months showed excellent efficacy, safety, stability, and predictability, with high patient satisfaction. .

摘要

目的

报告 10.00 至 14.00 屈光度(D)高度近视患者行小切口微透镜取出术(SMILE)的结果。

方法

本研究为前瞻性研究,采用卡尔蔡司公司的 VisuMax 飞秒激光行 SMILE 治疗高度近视。纳入标准为:等效球镜(SEQ)-9.00 至-14.00 D,柱镜不超过 7.00 D,最佳矫正远视力(CDVA)20/40 或更佳,年龄 21 岁或以上,适合行 SMILE。亚透镜厚度 220 µm 或以上,总未切割基质厚度 300 µm 或以上。患者随访 1 年。如有 12 个月数据,则采用标准结果分析;否则采用 3 个月数据。

结果

187 只眼中,181 只眼(96.8%)在 12 个月时可获得数据,4 只眼(2.1%)在 3 个月时可获得数据,2 只眼(1.1%)失访。平均尝试 SEQ 为-10.55 ± 1.00 D(范围:-9.00 至-12.99 D)。平均柱镜为-1.19 ± 0.83 D(范围:0.00 至-4.00 D)。术前 CDVA 为 20/20 或更佳的眼占 73%。术后未矫正远视力 20/20 或更佳的眼占 57%,20/25 或更佳的眼占 82%。与目标相比,平均 SEQ 为-0.22 ± 0.48 D(范围:-1.63 至+1.38 D),66%±0.50 D,93%±1.00 D。平均 SEQ 12 个月变化为-0.08 ± 0.34 D(范围:-1.75 至+0.88 D)。4%的眼视力下降一行,无一眼视力下降两行或更多。对比敏感度无变化。94%的患者对手术结果满意度为 8 分或更高,99%的患者满意度为 6 分或更高。

结论

3 至 12 个月时,SMILE 治疗大于-9.00 D 的近视的结果显示出极好的疗效、安全性、稳定性和可预测性,患者满意度高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验